EFMC-ISMC 2018

XXV EFMC International Symposium on Medicinal Chemistry

 Ljubljana, Slovenia    September 2-6, 2018

Award & Prize Lectures

Prof. Benjamin CRAVATT
PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
Activity-Based Proteomics - Protein and Ligand Discovery on a Global Scale
Prof. Christa MÜLLER
NAUTA AWARD FOR PHARMACOCHEMISTRY
Tools and Drugs for Purine Targets - Important Players in Inflammation and Cancer
Prof. Adam NELSON
UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY
How Best to Discover Bioactive Small Molecules?

Plenary Lectures

Dr Diego ARDIGO
The Therapeutic Challenge of the New Era: Developing and Making Available Life Changing Treatment to Patients with Rare Diseases
Prof. Tatjana AVSIC-ZUPANC
Zika Virus: An Old Virus with a New Face
Prof. Benjamin DAVIS
Sugars & Proteins: Glycomimetics to Target Infectious Disease
Dr Bayard HUCK
It’s a Small-Molecule World: Medicinal Chemistry Challenges and Opportunities for the Next Decade
Prof. Cristina NEVADO
Smart Chemical Probes: from Bromodomain Ligands to Natural Products
Dr Helga RÜBSAMEN-SCHAEFF
Development of Non-Nucleosidic Compounds against DNA Viruses of the Herpes Group. The Era After Nucleosides: Letermovir and Pritelivir
Prof. Peter H. SEEBERGER
Synthetic Glycoconjugate Vaccines against Bacterial Infections
 
 

Invited Speakers

Prof. Andrea ABLASSER
Intracellular DNA Sensing in Health and Disease
Prof. Andreas BENDER
Beyond Single-Target Activities: Using Polypharmacology and Systems Readouts for Compound Selection and Mode-of-Action Analysis
Dr Jonas BOSTRÖM
Stuck in a Rut with Old Chemistry
Dr Giovanni BOTTEGONI
In silico Polypolpharmacology
Dr Cedric BOULARAN
Use of Cyclic Dinucleotides (CDNs) to Induce Stimulator of Interferon Genes (STING)-Dependent Antitumor Immunity
Prof. Christina CHAI
Towards the Development of Novel Inhibitors for Chikungunya Virus Infection: Approaches in Structure-Activity-Metabolism Relationship (SAMR) Studies
Dr Philip CHAMBERLAIN
Targeting 'Undruggable' Transcription and Translation Factors for Degradation with Low Molecular Weight Cereblon Modulators
Prof. Steven CHARLTON
"Micro-Pharmacokinetics”: How Local Drug Concentration Influences Observed Binding Kinetics
Prof. Fener CHEN
Asymmetric Synthesis of Statin API as the Hypolipidemic Agents: The Evolution from the Chemical Kinetic Resolution to the Asymmetric Catalytic Technology (An Odessy)
Dr Diane COE
Modification of Cyclic Dinucleotides to Enhance Modulation of the Innate Immune Response
Dr Liesbeth DE LANGE
Target Binding Kinetics and its Relevance in the in vivo Context
Prof. Bernard FLYNN
Unravelling the Mysteries of the Sphinx: Novel Targets and Small-Molecule Therapeutics from the Sphingolipid Synthesis and Signaling Pathway
Prof. Karl GADEMANN
Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis
Prof. Antony GEE
PET Molecular Imaging – an Overview
Dr Riccardo GIOVANNINI
First Time Disclosure of BI 409306, a First in Class PDE9 Inhibitor for the Treatment of CNS Diseases
Prof. Stanislav GOBEC
Nonpeptidic Selective Inhibitors of Immunoproteasome
Dr Stephanie GUERET
Novel Hybrid Macrocyclic Modalities for Structure-Based Protein Mimetics
Dr Michael G. HAHN
Discovery of a Novel Oral NO- and Heme-Independent sGC Activator BAY 1101042
Dr Laura HEITMAN
Allosteric Modulation of the mGlu2 Receptor: from Structure-Kinetic Relationships to in vivo Efficacy
(2017 MedChemComm Emerging Investigator Lectureship)
Dr Jesus JIMENEZ-BARBERO
Breaking the Limits in Analyzing Carbohydrate Recognition by NMR
Prof. Stefan KRAUSS
Tankyrase Inhibitor Development: Evidence for Potential in Cancer Immune Therapy
Dr Jesper LAU
The Discovery of Semaglutide - A Journey from Ala Scan to Structural Design of GLP-1 Analogues
Prof. Stefan LAUFER
EGFR Triple Mutant L858R_T790M_ C797S Recent Set-Backs and New Hope in Fighting Mutant Non-Small Cell Lung Cancer
Dr David E. LEAHY
Artificial Intelligence. Not Just Another Name for in Silico Design
Dr Mark J. MILLAN
Multi-Functional Treatments for Multi-Factorial Neurodegenerative Disorders: the Challenge of Alzheimer's Disease
Dr Laurence MULARD
A Multidisciplinary Strategy to Synthetic Carbohydrate-Based Conjugates for Vaccination against Shigella: from Concept to First-in-Human Study
Dr Mikihiko NAITO
Recent Advances in Bifunctional Degrader Molecules (e.g. SNIPER) for Targeted Protein Degradation via the Ubiquitin Proteasome System; Status and Outlook
Prof. Hermen OVERKLEEFT
Activity-Based Glycosidase Profiling in Biomedicine and Biotechnology
Prof. Roberto PELLICCIARI
Obeticholic Acid, Leading in the NASH Race. History and Perspectives
Dr Robert PULZ
Discovery of LOU064, a Covalent BTK Inhibitor with Best in Class Selectivity
Dr Laura QUARANTA
Synthesis and Fungicidal Activity of a New Family of Oxysterol Binding Protein Inhibitors
Dr Murali RAMACHANDRA
Small Molecule Immune Checkpoint Antagonists for Cancer Therapy
Dr Hasane RATNI
Discovery of RG7916, a Selective SMN2 Splicing Modifier for the Treatment of Spinal Muscular Atrophy
Dr Joachim RHEINHEIMER
Natural Products as Leads in Agrochemistry
Dr Raphaël RODRIGUEZ
An Iron Hand over Cancer Stem Cells
Dr Webster L. SANTOS
Controlling Sphingosine-1-Phosphate Levels as a Therapeutic Strategy
Dr Laurent SCHIO
Design and Rationale for Exquisite Selectivity of Preclinical and Clinical Kinase Inhibitors
Dr Magnus SCHOU
PET in Neuroscience Drug Discovery and Development
Mr Marwin SEGLER
Computer-Aided Synthesis Planning
Prof. David SELWOOD
C-Natruiretic Peptide Agonists for Cardiovascular Disease
Prof. Satoshi SHUTO
Design and Synthesis of Congerners of Cyclic ADP-Ribose, a Ca2+-Mobilizing Second Messenger, Toward Identification of the Target Protein
Prof. Richard B. SILVERMAN
Design, Synthesis, and Mechanism of β-Glucocerebrosidase Activators for Gaucher’s and Parkinson’s Diseases
Prof. Jurij SVETE
New Chemical Libraries in Exploration of Chemical Space
Dr Nick TERRETT
Cell Permeability with Beyond ‘Rule of 5’ Modalities – Do We Understand How This Works?
Dr Martin K. THOMSEN
In vivo Anti-Viral and -Tumor Effect Of 3’3’-cAIMP STING Activation
Dr Nicolas THOMÄ
The Zinc-Degrome
Dr Jan Willem THURING
Discovery of JNJ-64619178 as a Potent and Selective PRMT5 Inhibitor for the Treatment of Lung and Hematologic Cancers
Prof. Peter TIMMERMAN
Tricyclic Peptides via Templated Tandem CLIPS/CUAAC Cyclizations
Prof. Matthew TODD
All Bugs are Shallow: Open Source Drug Discovery
Dr Gergely TOTH
Targeting the Monomeric Intrinsically Disordered Structural State of Tau and Alpha-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Alzheimer's and Parkinson’s Disease
Dr Wes TROTTER
Cyclic Dinucleotide STING Agonists as Anti-Tumor Agents
Dr David TULLY
Discovery of LJN452 (Tropifexor), a Highly Potent, Non-Bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and NASH
Dr Sean C. TURNER
Positive Allosteric Modulators of the GABA-B Receptor
Dr Anne VALADE
The Value of Orthogonal Techniques for Elucidating Binding Site(s) of GPCR Allosteric Modulators: a Case Study With Positive Allosteric Modulators of Dopamine Receptors
Dr Eric VALEUR
New Modalities for Complex and Unprecedented Biological Targets
Dr Willem VAN HOORN
Re-Energising Small Molecule Drug Discovery
Prof. Dmytro VOLOCHNYUK
Synthesis of MedChem-Relevant Gem-Difluorocycloalkane Building Blocks
Dr Franz VON NUSSBAUM
A New Target in Fungal Protein Biosynthesis: Shared Learnings for AgChem and MedChem
Prof. Hans WANDALL
Targeting of Cancer Specific Glycopeptide Epitopes
Dr Sven WEILER
Active Site Inhibitors of Sphingosine 1-Phosphate Lyase - Exploring Novel Biology with Tool Compounds
Prof. Bert WINDHORST
PET for Oncology Drug Discovery and Development
Dr Wolfgang WRASIDLO
Discovery of Peptidomimetics Targeting Protein-Protein Interactions of Alpha-Synuclein
Prof. Hang YIN
Small Molecule Immunomodulators that Target Toll-Like Receptors
Prof. Xumu ZHANG
Practical Asymmetric Hydrogenation
Prof. Markus ZWECKSTETTER
Understanding Aggregation Inhibition of Alpha-Synuclein and Tau by Small Molecules
 

Oral Communications

Dr Amjad ALI
Discovery and Clinical Evaluation of MK-8150, a Novel Nitric Oxide Donor with a Unique Mechanism of Nitric Oxide Release
Dr Steve ANDREWS
Brain-Penetrant Autophagy Modulators for Treating Neurodegenerative Diseases
Dr Bernard BARLAAM
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 that Enables Transient Target Engagement for the Treatment of Haematological Malignancies
Dr Stefan BÄURLE
First Disclosure of the Clinical Candidate BAY-840, a Potent And Selective hBradykinin B1 Antagonist for the Treatment of Chronic Inflammatory Diseases, Generated within the Bayer-Evotec Strategic Alliance
Dr Jose CID
Metabotropic Glutamate Receptor Type 2 Positive Allosteric Modulators (mGlu2 Receptor PAMS) as a Transformational Epilepsy Treatment
Prof. Gabriele COSTANTINO
Targeting Non Essential Bacterial Targets as a Novel Route to Counteract Bacterial Resistance
Dr Marton CSEKEI
EFMC Prize for a Young Medicinal Chemist in Industry
The Challenges of Restoring Programmed Cell Death Through MCL1 Inhibition
Dr Vincent DARMENCY
Discovery of Candidates for PET Molecular Imaging of Pathological TDP-43 Aggregates in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Patients
Ms Ana Rita DE CARVALHO ACURCIO
New Small-Molecule Immune Checkpoint Inhibitors: A Step Forward in Cancer Immunotherapy
Dr Al DOSSETTER
Potency and Patents, New Arenas for Matched Molecular Pair Analysis in the AI World
Dr Maria DUCA
Synthetic Small-Molecule RNA Ligands: Scope and Therapeutic Applications
Dr Peter ETTMAYER
Chemical Probes for New Therapeutic Concept Discovery
Dr Esther FERNANDEZ
Identification of New Antimalarial GSK607: An Example of Adaptive and Differentiated Early Drug Development
Prof. Paul FISH
Development of Potent, Selective, CNS Penetrant Small Molecule Inhibitors of Notum to Potentiate Wnt Signaling for the Maintainance of Synaptic Function in Alzheimer’s Disease
Dr Carles GALDEANO
Drugging the Fbw7 E3 Ligase with a Combined Computational and Biophysical Approach
Dr Matthias GEHRINGER
Buruli Ulcer and the mTOR Pathway: Total Synthesis, Structure-Activity and Target Elucidation Studies of Mycolactones
Ms Victoria GEORGI
Large-Scale Analysis of Kinase Inhibitors' Target Binding Kinetics and its Implications for Drug Discovery
Dr Brian GERSTENBERGER
Discovery of the TYK2 Selective Inhibitor PF-6826647 for the Treatment of Crohn’s Disease, and Other Autoimmune Conditions
Prof. Antimo GIOIELLO
Integrated System for the Expedited Generation and Characterization of Drug-Like Libraries for Hit-to-Lead Explorations
Dr Peter GROOTENHUIS
IUPAC-Richter Prize Lecture
Discovery of CFTR Modulators For The Treatment of Cystic Fibrosis
Dr Steven HOWARD
ASTX660, the First Fragment-Derived IAP Antagonist in the Clinic
Prof. James JANETKA
Glycoside Antagonists of Bacterial Lectins: New Treatment Options for Recurrent and Antibiotic Resistant UTI
Dr Allan JORDAN
Discovery of First-in Class, Selective and Noncovalent Small Molecule Inhibitors of DNMT1
Dr Jamie KNIGHT
Discovery of GDC-0077: A Highly Selective Inhibitor and Degrader of Mutant PI3K-Alpha
Dr Rainer MACHAUER
The Discovery of CNP520, an Amino-1,4-Oxazine BACE Inhibitor in Prevention Studies
Dr Daniel MERK
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Treat Non-Alcoholic Steatohepatitis
(EFMC-YMCS Presentation Prize)
Ms Anna MIGGLAUTSCH
Development of Small-Molecule Inhibitors of Adipose Triglyceride Lipase (ATGL)
Mr Andrew MONTGOMERY
Development of Novel Sialyltransferase Inhibitors via Computer Aided Drug Design
Dr Christian OTTMANN
Small-Molecule Stabilization of Protein-Protein Interactions by Natural Products, Supramolecular Ligands, Fragments and Macrocycles
Dr Vladimir A. PALYULIN
AMPA Receptor Positive Allosteric Modulators Based on New Scaffolds: Design, Synthesis, and Studies
Mr Tamas REVESZ
Charting the Structure-Resistance Landscape of Novel Antibiotics
Dr Shabnam SHAABANI
Small Molecules Inhibiting PD1-PDL1 Immune Checkpoint
Dr Hong SHEN
Anti-HBV Drug Discovery Enabled by Structure-Based Drug Design and Phenotypic Screening
Dr Alice SOSIC
Mechanisms of HIV-1 Nucleocapsid Protein Inhibition by Small Molecules Targeting RNA
Dr Hauke SZILLAT
Discovery and Optimization of Non-Covalent, Selective, and Bioavailable Small Molecule Inhibitors of the KEAP1-Nrf2 Pathway
Dr Alexander TITZ
EFMC Prize for a Young Medicinal Chemist in Academia
Carbohydrate-binding Proteins as Targets for Anti-Infectives and Diagnostics: ESKAPE pathogen Pseudomonas aeruginosa and its Lectins
Dr Juraj VELCICKY
Discovery of SPL-707: A Potent, Selective, and Orally Bioavailable SPPL2a Inhibitor
Dr Fredrik ZETTERBERG
The First Class of Orally Available Mono-Saccharide Galectin-3 Inhibitors for Treatment of Fibrosis (NASH) and Cancer